Latest News
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
INCHEON, Korea – Feb 16, 2025 -- Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-ds
FDA Approves Gomekli (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
STAMFORD, Conn., Feb. 11, 2025 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S.
FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections
NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), as the first an
Mr. James Ho, the founder of CliniExpert, was invited to attend the 71st Indian Pharmaceutical Congress and was awarded the International Contribution Award
On December 20-22, 2019, at the invitation of the Committee of Indian Drug Control Officials, Mr. James Ho, CEO of Beijing Memorial Pharmaceutical Research Co., Ltd. went to Chennai, the fourth larges
Organized by Cliniexpert, China Pharma Summit 2021 in Beijing & First China International Generic Drug Development Forum was Successfully Held
From June 3 to 4, 2021, the "China Pharma Summit 2021 in Beijing & First China International Generic Drug Development Forum" hosted by Beijing Memorial Pharmaceutical Research Co., Ltd.
Try the best and demand every team member as the one who Keeps His Word. - James Ho
China Industrial Economy News reporter Linlin Zhao -- Over the past 40 years of reform and opening up, the ranks of small and medium-sized enterprises have become larger and larger, and they have beco
James Ho, Founder of The CliniExpert Answered Questions of Reportes
Q:Would you give us a brief about CliniExpert? James Ho:Based in China, we are offering services to the global pharmaceutical research industry, esp. for the supply of the investigational product. We
In the "post-epidemic" era, How Can Chinese Clinical Comparators Save Your Cost ?
What is the "post-epidemic" era? My colleague Mr.Zhang once used to having noodles for lunch in the restaurant which is near the company for several years. But in 2020, this restaurant was c
FDA Approves Onapgo (apomorphine hydrochloride) for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease
ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Jan. 30, 2025 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), an or
FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
FDA Approves Avtozma (tocilizumab-anoh), a Biosimilar to Actemra
JERSEY CITY, N.J., Jan. 30, 2025 -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Avtozma® (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutan
News
- CanalLotus Biotech -
Int'l Clinical Service Expert
We are the leader
Because of our professionism











